Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Running, not enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Neovascular Age-related Macular Degeneration (nAMD)

In brief

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).

Key facts

Study ID
NCT05769153
Run by
Alcon Research
People needed
139
Starts
2023-12-06
Expected to finish
2027-10-01
Last updated by the study team
2026-05-26

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.